Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473910 | 0.82 | CHKA (0.49) | ALDH1A1CHKA | |
| SCHEMBL15471355 | 0.75 | MEN1 (0.44) | PIK3CDALDH1A1CHKACHRM4 | |
| SCHEMBL20458924 | 0.74 | CXCR4 (0.47) | CHRM1 | |
| SCHEMBL16538615 | 0.73 | CHRM5 (0.38) | MLNRKCNH2CHRM5CHRM4CHRM1 | |
| SCHEMBL209485 | 0.72 | SIGMAR1 (0.41) | MLNRKCNH2CHRM5TLR9TLR7 | |
| SCHEMBL19221567 | 0.72 | CCR2 (0.51) | ALDH1A1CHKACYP2C9 | |
| SCHEMBL12424288 | 0.71 | ALDH1A1 (0.45) | KCNH2CHRM5ALDH1A1TLR9TLR7 | |
| SCHEMBL209789 | 0.71 | MEN1 (0.40) | MLNRCHRM5ALDH1A1FNTAFNTB | |
| SCHEMBL13007674 | 0.69 | CARM1 (0.38) | — | |
| SCHEMBL13007670 | 0.68 | SIGMAR1 (0.60) | CHKAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670212-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CD 1/4885MLNR 2310/4885KCNH2 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.